Amgen Inc. $AMGN Shares Sold by Strs Ohio

Strs Ohio trimmed its holdings in Amgen Inc. (NASDAQ:AMGN) by 7.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 151,796 shares of the medical research company’s stock after selling 11,790 shares during the quarter. Strs Ohio’s holdings in Amgen were worth $42,837,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in AMGN. Vanguard Group Inc. lifted its stake in Amgen by 1.6% during the second quarter. Vanguard Group Inc. now owns 53,711,570 shares of the medical research company’s stock valued at $14,996,807,000 after purchasing an additional 841,117 shares during the last quarter. State Street Corp boosted its holdings in Amgen by 0.6% during the second quarter. State Street Corp now owns 29,357,026 shares of the medical research company’s stock worth $8,196,775,000 after buying an additional 177,035 shares in the last quarter. Geode Capital Management LLC grew its position in Amgen by 2.3% in the second quarter. Geode Capital Management LLC now owns 13,018,617 shares of the medical research company’s stock worth $3,619,489,000 after buying an additional 291,271 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Amgen by 5.6% in the second quarter. Charles Schwab Investment Management Inc. now owns 12,893,677 shares of the medical research company’s stock valued at $3,600,043,000 after buying an additional 687,735 shares in the last quarter. Finally, Laurel Wealth Advisors LLC lifted its position in shares of Amgen by 27,765.8% during the 2nd quarter. Laurel Wealth Advisors LLC now owns 6,700,621 shares of the medical research company’s stock valued at $1,870,880,000 after acquiring an additional 6,676,575 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen announced a dividend increase to $2.52, reinforcing its income profile and making the stock more attractive to dividend-focused investors. This supports longer-term investor demand. Amgen (NASDAQ:AMGN) Has Announced That It Will Be Increasing Its Dividend To $2.52
• Positive Sentiment: Amgen expanded its obesity/GLP‑1 strategy via a collaboration with Ro, signaling potential new mid-term revenue streams if programs progress. Pipeline progress tends to boost investor sentiment for growth prospects. Amgen (AMGN) expands obesity strategy with Ro collaboration on GLP-1 therapies
• Positive Sentiment: The stock recently hit a 52-week high, reflecting recent buyer interest and validation of recent corporate moves and sentiment around the pipeline. Amgen stock hits 52-week high at $346.41
• Neutral Sentiment: Zacks notes AMGN is a trending stock on its platform, outlining investor attention and search interest but providing no new catalyst; useful context on market interest but not a direct driver. Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock
• Neutral Sentiment: Analyst commentary and deep-dive pieces (e.g., Seeking Alpha on MariTide obesity/T2D potential) highlight upside from R&D, but these are longer‑horizon, research-driven views rather than immediate catalysts. Amgen: A Buy In 2026 On Exciting MariTide Obesity – T2D Potential
• Negative Sentiment: Sagebrush has sued Amgen over disputes tied to the 340B program, introducing legal, reimbursement and stakeholder-risk that could pressure margins or create uncertainty around commercial terms. Litigation and policy disputes can weigh on near-term sentiment. Sagebrush sues Amgen over 340B program row
• Negative Sentiment: Sanford C. Bernstein downgraded Amgen to a Hold / lowered its rating, which can trigger selling or reduced conviction among institutional investors and contribute to downward pressure. Bernstein downgrades Amgen (AMGN) to a Hold

Insider Transactions at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 3,139 shares of the business’s stock in a transaction dated Thursday, November 20th. The stock was sold at an average price of $337.26, for a total value of $1,058,659.14. Following the transaction, the senior vice president owned 7,225 shares in the company, valued at $2,436,703.50. The trade was a 30.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Murdo Gordon sold 6,879 shares of the company’s stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $336.83, for a total value of $2,317,053.57. Following the completion of the transaction, the executive vice president directly owned 41,923 shares in the company, valued at approximately $14,120,924.09. The trade was a 14.10% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 10,908 shares of company stock valued at $3,674,966. 0.76% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on AMGN shares. Deutsche Bank Aktiengesellschaft lifted their target price on Amgen from $280.00 to $285.00 and gave the stock a “hold” rating in a report on Tuesday, November 11th. BMO Capital Markets lifted their price target on Amgen from $335.00 to $372.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 3rd. Morgan Stanley cut their price objective on Amgen from $329.00 to $304.00 and set an “equal weight” rating on the stock in a report on Friday, December 12th. Argus raised their target price on shares of Amgen from $310.00 to $360.00 and gave the stock a “buy” rating in a report on Tuesday, December 30th. Finally, Sanford C. Bernstein downgraded shares of Amgen from an “outperform” rating to a “market perform” rating and set a $335.00 target price on the stock. in a research report on Tuesday. Two analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Amgen presently has a consensus rating of “Moderate Buy” and an average price target of $339.24.

Amgen Price Performance

Shares of AMGN opened at $344.75 on Friday. The business’s 50-day moving average is $332.07 and its 200-day moving average is $307.54. The company has a debt-to-equity ratio of 5.45, a current ratio of 1.28 and a quick ratio of 0.99. The company has a market capitalization of $185.64 billion, a price-to-earnings ratio of 26.64, a P/E/G ratio of 3.09 and a beta of 0.45. Amgen Inc. has a fifty-two week low of $261.43 and a fifty-two week high of $349.98.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, November 4th. The medical research company reported $5.64 EPS for the quarter, topping the consensus estimate of $5.01 by $0.63. Amgen had a net margin of 19.47% and a return on equity of 162.59%. The business had revenue of $9.56 billion during the quarter, compared to analysts’ expectations of $8.98 billion. During the same period last year, the company posted $5.58 earnings per share. The firm’s quarterly revenue was up 12.4% compared to the same quarter last year. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. Equities research analysts expect that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 13th will be issued a dividend of $2.52 per share. The ex-dividend date is Friday, February 13th. This represents a $10.08 annualized dividend and a dividend yield of 2.9%. This is an increase from Amgen’s previous quarterly dividend of $2.38. Amgen’s dividend payout ratio is presently 77.90%.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.